GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (BOM:532649) » Definitions » Cyclically Adjusted PB Ratio

Nectar Lifesciences (BOM:532649) Cyclically Adjusted PB Ratio : (As of Jun. 04, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Nectar Lifesciences Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nectar Lifesciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Nectar Lifesciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nectar Lifesciences Cyclically Adjusted PB Ratio Chart

Nectar Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nectar Lifesciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nectar Lifesciences's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nectar Lifesciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nectar Lifesciences's Cyclically Adjusted PB Ratio falls into.


;
;

Nectar Lifesciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Nectar Lifesciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Nectar Lifesciences's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0/158.3229*158.3229
=0.000

Current CPI (Dec. 2024) = 158.3229.

Nectar Lifesciences Quarterly Data

Book Value per Share CPI Adj_Book
200603 14.231 45.521 49.495
200703 14.830 48.581 48.330
200803 18.653 52.407 56.351
200903 19.923 56.615 55.715
201003 27.675 65.030 67.378
201103 32.156 70.768 71.940
201203 34.980 76.889 72.028
201303 38.687 85.687 71.482
201403 41.338 91.425 71.586
201503 40.222 97.163 65.540
201603 42.543 102.518 65.701
201703 44.889 105.196 67.559
201803 47.207 109.786 68.077
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 49.280 118.202 66.007
201906 0.000 120.880 0.000
201909 49.943 123.175 64.194
201912 0.000 126.235 0.000
202003 50.661 124.705 64.318
202006 0.000 127.000 0.000
202009 49.525 130.118 60.260
202012 0.000 130.889 0.000
202103 47.357 131.771 56.900
202106 0.000 134.084 0.000
202109 47.520 135.847 55.382
202112 0.000 138.161 0.000
202203 48.511 138.822 55.326
202206 0.000 142.347 0.000
202209 47.684 144.661 52.187
202212 0.000 145.763 0.000
202303 47.471 146.865 51.175
202306 0.000 150.280 0.000
202309 47.598 151.492 49.744
202312 0.000 152.924 0.000
202403 47.679 153.035 49.327
202406 0.000 155.789 0.000
202409 48.061 157.882 48.195
202412 0.000 158.323 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nectar Lifesciences  (BOM:532649) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Nectar Lifesciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Nectar Lifesciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nectar Lifesciences Business Description

Traded in Other Exchanges
Address
SCO 38-39, Sector 9-D, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.

Nectar Lifesciences Headlines

No Headlines